Navigation Links
Accumetrics, Inc. Announces Distribution Channels in Israel and Cyprus
Date:6/9/2009

SAN DIEGO, June 9 /PRNewswire/ -- Accumetrics, Inc. announces today it has signed new distribution agreements for its VerifyNow(R) System in both Israel and Cyprus. Medtechnica, Ltd. will oversee distribution of all VerifyNow products in Israel, while Z.S. Curemed, Ltd. will be the sole distribution channel in Cyprus. These distribution agreements continue to expand Accumetrics' reach in both scope and geography, and add to the growing numbers of countries outside of the United States and Europe where physicians have access to the VerifyNow System.

The VerifyNow System assesses response to antiplatelet therapies, such as aspirin, Plavix(R) and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their patients on antiplatelet medications are receiving the optimal benefit.

"We're extremely excited to see distribution of our VerifyNow System reach Israel and Cyprus. We have chosen these partners based on their demonstrated expertise and knowledge of our markets in their respective territories," said Timothy I. Still, President and CEO of Accumetrics. "These partnerships continue to emphasize our focus on expanding our global distribution channels, and support our vision of providing physicians worldwide access to critical information for managing their cardiovascular patients on antiplatelet therapies."

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing e
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial
2. Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited
3. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
4. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
5. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
6. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
7. Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors
8. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
9. Life Spine Announces Appointment of Todd Fanning as Vice President of Sales
10. CareFusion Announces Board of Directors, Progress on Alaris Consent Decree
11. ThinIdentity(TM) Announces Two New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Mediterranean diet associated with reduced risk of depression 10311 1Mediterranean diet associated with reduced risk of depression 10311 2Common herbicides and fibrates block nutrient sensing receptor found in gut and pancreas 10307 1Common herbicides and fibrates block nutrient sensing receptor found in gut and pancreas 10307 2Miscarriage Treatment Wont Harm Future Fertility 3A Study 59205 1Miscarriage Treatment Wont Harm Future Fertility 3A Study 59205 2